Form 8-K · Current report
Schlumberger 8-K, filed Oct 6, 2026
- Filed
- CIK
- 0000087347
- Accession no.
- 0001193125-26-415617
Summary
SLB Limited's board of directors elected Jing Ulrich, formerly vice chairman of investment banking at JPMorgan Chase, as a director effective October 5, 2026, with seats on the board's Audit and Finance Committees. Ulrich will serve until the next annual general meeting, when she will stand for re-election.
Key points
- The appointment took effect immediately on October 5, 2026.
- Ulrich served as vice chairman of investment banking at JPMorgan Chase from 2021 until July 1, 2026, after holding senior roles there including vice chairman of global banking and Asia Pacific from 2005 to 2021.
- She has been a member of adidas AG's supervisory board since 2019, of Swarovski International Holding's board since 2025, and of The Wella Company's board since April 2026.
- SLB said there are no transactions with Ulrich reportable under Item 404(a) of Regulation S-K.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
Items reported
- 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
From the filing
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 5, 2026, the Board of Directors (the “Board”) of SLB Limited (“SLB” or the “Company”) elected Ms. Jing Ulrich to serve as a member of the Board, effective immediately. Ms. Ulrich will also serve on the Board’s Audit Committee and Finance Committee. There are no transactions with Ms. Ulrich that would be reportable under Item 404(a) of Regulation S-K. Ms. Ulrich brings extensive investment banking and capital-markets experience, as well as deep knowledge of global financial markets. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.